First generation - Tau Aggregation Inhibitor
rember™ is an orally available small molecule that has been shown to be an effective Tau aggregation inhibitor. The Tau aggregation pathology is a disease target of fundamental importance for the control of Alzheimer’s disease. rember™ has two effects in Alzheimer’s disease. First, it blocks the formation of Tau oligomers and their conversion to Paired helical filaments. Second, the more important effect of rember™ is its ability to solvate / dissolve Tau oligomers and paired helical filaments into the short truncated monomers which comprise the proteolytically stable core of the Paired helical filaments. Once reduced to its constituent monomers, the truncated Tau monomers become susceptible to proteases and are of a size which can be cleared efficiently through the proteasomal clearance pathway. We are currently evaluating rember™ in clinical trials for Alzheimers disease.

Second Generation –Tau Aggregation Inhibitor
LMT-X is another orally available Tau aggregation inhibitor currently in preclinical development. It has demonstrated potent effects on Tau pathology in our Tau Transgenic animal models.